Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / TALS - Talaris Therapeutics a buy at H.C. Wainwright on cell therapy programs

TALS - Talaris Therapeutics a buy at H.C. Wainwright on cell therapy programs

Talaris Therapeutics Inc.
  • H.C. Wainwright has initiated Talaris Therapeutics ( NASDAQ: TALS ) with a buy rating saying that the biotech's allogeneic hematopoietic stem cell (Allo-HSCT) transplantation platform can transform the standard of care in many areas.
  • The firm has a $18 price target (~644% upside based on Wednesday's close).
  • Analyst Raghuram Selvaraju noted that Talaris' ( TALS ) platform has the potential to improve care in solid organ transplantation, autoimmune diseases, and severe blood, immune and metabolic disorders.diseases and severe blood, immune and metabolic disorders

For further details see:

Talaris Therapeutics a buy at H.C. Wainwright on cell therapy programs
Stock Information
Company Name: Talaris Therapeutics Inc.
Stock Symbol: TALS
Market: NASDAQ
Menu
TALS TALS Quote TALS Short TALS News TALS Articles TALS Message Board
Get TALS Alerts

News, Short Squeeze, Breakout and More Instantly...